Health
Cancer Vaccines Enter a New Clinical Era
A Nature Medicine review traces the rapid advance of personalized mRNA cancer vaccines from experimental concept to active clinical development, marking a turning point for cancer immunotherapy.
Key Takeaways
- Personalized mRNA cancer vaccines use tumor sequencing to target neoantigens unique to each patient's cancer
- Moderna/Merck mRNA-4157 showed significant melanoma recurrence reduction in Phase 2, driving broader clinical expansion
- Combination approaches pairing vaccines with checkpoint inhibitors are advancing across multiple tumor types
- Multiple Phase 3 trials now underway will determine if cancer vaccines become standard-of-care treatment
DE
DT Editorial AI··via nature.com